| Title: | Interpretable machine learning leverages proteomics to improve cardiovascular disease risk prediction and biomarker identification |
| Journal: | Communications Medicine |
| Published: | 19 May 2025 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/40389651/ |
| DOI: | https://doi.org/10.1038/s43856-025-00872-0 |
| URL: | https://www.nature.com/articles/s43856-025-00872-0.pdf |
Publication 15298
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
BackgroundCardiovascular diseases (CVDs) rank amongst the leading causes of long-term disability and mortality. Predicting CVD risk and identifying associated genes are crucial for prevention, early intervention, and drug discovery. The recent availability of UK Biobank Proteomics data enables investigation of blood proteins and their association with a variety of diseases. We sought to predict 10 year CVD risk using this data modality and known CVD risk factors.MethodsWe focused on the UK Biobank participants that were included in the UK Biobank Pharma Proteomics Project. After applying exclusions, 50,057 participants were included, aged 40-69 years at recruitment. We employed the Explainable Boosting Machine (EBM), an interpretable machine learning model, to predict the 10 year risk of primary coronary artery disease, ischemic stroke or myocardial infarction. The model had access to 2978 features (2923 proteins and 55 risk factors). Model performance was evaluated using 10-fold cross-validation.ResultsThe EBM model using proteomics outperforms equation-based risk scores such as PREVENT, with a receiver operating characteristic curve (AUROC) of 0.767 and an area under the precision-recall curve (AUPRC) of 0.241; adding clinical features improves these figures to 0.785 and 0.284, respectively. Our models demonstrate consistent performance across sexes and ethnicities and provide insights into individualized disease risk predictions and underlying disease biology.ConclusionsIn conclusion, we present a more accurate and explanatory framework for proteomics data analysis, supporting future approaches that prioritize individualized disease risk prediction, and identification of target genes for drug development.</p>
17 Authors
- Héctor Climente-González
- Min Oh
- Urszula Chajewska
- Roya Hosseini
- Sudipto Mukherjee
- Wei Gan
- Matthew Traylor
- Sile Hu
- Ghazaleh Fatemifar
- Jonas Ghouse
- Paul Pangilinan Del Villar
- Erik Vernet
- Nils Koelling
- Liang Du
- Robin Abraham
- Chuan Li
- Joanna M. M. Howson
Enabling scientific discoveries that improve human health